AVONTEC’s drug candidate AVT-02 UE for the treatment of inflammatory skin diseases has entered a multiple dosing Phase I study

Martinsried, (PresseBox) - The biopharmaceutical company AVONTEC GmbH, focused on the development and commercialization of novel therapeutic treatments for inflammatory diseases, today announced that its drug candidate AVT-02 UE for the treatment of inflammatory skin diseases has entered into a multiple dosing Phase I study.

This Phase I study will be conducted in Germany. Subjects will be treated for a period of four weeks. Besides safety this study is intended to prove changes of functional parameters of the skin during treatment with the drug candidate AVT 02 UE. The German regulatory authority BfArM has approved the conduct of this Phase I study based on a comprehensive dermal toxicology and pharmacology package as well as the promising results of the clinical studies conducted so far.

Dr. Wolfgang Barth, Chief Development Officer at Avontec said: "This study approval is an important milestone in our development program for AVT-02 UE in inflammatory skin diseases and will be the basis for further clinical efficacy studies. It demonstrates the soundness and validity of our preclinical package together with the excellent safety of AVT-02 UE demonstrated so far."

About AVT-02 UE
Avontec's drug candidate AVT-02 UE for inflammatory skin diseases contains a short, double-stranded oligonucleotide "decoy" that effectively inhibits STAT-1, a transcription factor shown to be strongly involved in the regulation of chronic inflammation. AVT-02 UE reduced inflammation in several pharmacological animal models and has demonstrated statistically significant efficacy on relevant clinical endpoints in a pilot proof of concept Phase IIa study in psoriasis. In addition, AVT-02 UE was proven to be safe and well tolerated.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.